Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (41-50 of 303) with videos related to

Pageof 31
Sort By:
Journal of Oncology Practice|December 13, 2016
Role of Biologics in First-Line Treatment of Colorectal CancerAmit Mahipal, Axel Grothey
Therapeutic Advances in Medical Oncology|February 17, 2017
European Society for Medical Oncology Copenhagen update: potential practice-changing findingsGordon Mallarkey, Axel Grothey
The Lancet. Oncology|May 19, 2015
The role of regorafenib in metastatic colorectal cancerRachel Riechelmann, Axel Grothey
Expert Review of Anticancer Therapy|June 10, 2006
First- and second-line therapy of metastatic colorectal cancerShelby Terstriep, Axel Grothey
Oncology (Williston Park, N.Y.)|February 21, 2009
Individualizing therapy for metastatic colorectal cancerJoleen Turja, Axel Grothey
Therapeutic Advances in Gastroenterology|July 15, 2021
Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancerVanessa Wookey, Axel Grothey
BMJ Case Reports|April 24, 2015
Metastatic extramammary Paget's disease responding to weekly paclitaxelVania Phuoc, Axel Grothey
Oncology (Williston Park, N.Y.)|January 22, 2016
Adjuvant Therapy After Resection of Metastatic Colorectal Cancer: Clear Proof of Principle in This SettingAnelisa Coutinho, Axel Grothey
JAMA Network Open|December 16, 2020
Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the WayNoam VanderWalde, Axel Grothey
The Lancet. Oncology|February 5, 2020
EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?Sepideh Gholami, Axel Grothey
Pageof 31

Showing results (41-50 of 303) with videos related to

Sort By:
Pageof 31
Journal of Oncology Practice|December 13, 2016
Role of Biologics in First-Line Treatment of Colorectal CancerAmit Mahipal, Axel Grothey
Therapeutic Advances in Medical Oncology|February 17, 2017
European Society for Medical Oncology Copenhagen update: potential practice-changing findingsGordon Mallarkey, Axel Grothey
The Lancet. Oncology|May 19, 2015
The role of regorafenib in metastatic colorectal cancerRachel Riechelmann, Axel Grothey
Expert Review of Anticancer Therapy|June 10, 2006
First- and second-line therapy of metastatic colorectal cancerShelby Terstriep, Axel Grothey
Oncology (Williston Park, N.Y.)|February 21, 2009
Individualizing therapy for metastatic colorectal cancerJoleen Turja, Axel Grothey
Therapeutic Advances in Gastroenterology|July 15, 2021
Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancerVanessa Wookey, Axel Grothey
BMJ Case Reports|April 24, 2015
Metastatic extramammary Paget's disease responding to weekly paclitaxelVania Phuoc, Axel Grothey
Oncology (Williston Park, N.Y.)|January 22, 2016
Adjuvant Therapy After Resection of Metastatic Colorectal Cancer: Clear Proof of Principle in This SettingAnelisa Coutinho, Axel Grothey
JAMA Network Open|December 16, 2020
Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the WayNoam VanderWalde, Axel Grothey
The Lancet. Oncology|February 5, 2020
EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?Sepideh Gholami, Axel Grothey
Pageof 31